Clinical Trial Update: Ladarixin With Sotorasib in Advanced NSCLC [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial update notes the combination of ladarixin with sotorasib for advanced non-small cell lung cancer with KRAS G12C mutation, currently rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Ladarixin (ladarixin)
• sotorasib (sotorasib)

Snippet

Sponsor: NYU Langone Health | Conditions: Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation | Phase 1 | Status: RECRUITING